Last reviewed · How we verify
CEFOPERAZONE SODIUM
Cefoperazone Sodium is a marketed antibiotic with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and long-standing use in treating bacterial infections. The primary risk is the potential increase in generic competition following the 2028 patent expiry.
At a glance
| Generic name | CEFOPERAZONE SODIUM |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
Common side effects
Key clinical trials
- Comparison of the Clinical Efficacy of Ampicillin/Sulbactam and Cefoperazone/Sulbactam Against Multidrug Resistant Acinetobacter Baumannii Infections in Critically Ill Patients (NA)
- Concentration Monitoring of Anti-infective Drugs in Human Cerebrospinal Fluid and Its Clinical Application
- Establishment of Risk Factors Model of Drug-induced Coagulation Disorder Caused by Cefoperazone Sulbactam Sodium
- Prevention of Cefoperazone-induced Coagulopathy (PHASE4)
- Evaluate Bioequivalence of Burotam (1/1 g/Vial) (PHASE4)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Safety and Efficacy of Vancomycin Plus Beta-lactams
- Study on Ceftazidime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CEFOPERAZONE SODIUM CI brief — competitive landscape report
- CEFOPERAZONE SODIUM updates RSS · CI watch RSS